STOCK TITAN

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.

Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.

Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.

Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.

Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.

Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.

For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.

Rhea-AI Summary

Exelixis, Inc. (NASDAQ: EXEL) mourns the loss of Gisela M. Schwab, M.D., Chief Medical Officer, who passed away after a medical leave since June 18, 2021. Her leadership and contributions significantly advanced the company’s clinical development efforts, transitioning Exelixis into a commercial biotechnology firm. The news follows the recent passing of Jon Berndt, Senior VP of Sales. Both were influential figures in the oncology field, leaving behind a legacy of dedication and impact on patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) announced participation in several virtual investor conferences in September 2021. The schedule includes:

  • Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 1:15 PM EDT.
  • H.C. Wainwright 23rd Annual Global Investment Conference available on-demand from September 13 at 7:00 AM EDT.
  • BofA Securities Global Healthcare Conference on September 15 at 5:35 PM BST.
  • Cantor 2021 Virtual Global Healthcare Conference on September 29 at 2:40 PM EDT.

Webcasts will be accessible via their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences
-
Rhea-AI Summary

Exelixis announces that Takeda and Ono received approval from the Japanese Ministry of Health to market CABOMETYX in combination with OPDIVO for treating unresectable or metastatic renal cell carcinoma (RCC). This approval follows the success of the CheckMate -9ER trial, which showed that the combination significantly improved overall survival and doubled median progression-free survival compared to sunitinib. Exelixis is set to receive a $20 million milestone payment from Takeda upon the first commercial sale in Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
Rhea-AI Summary

Exelixis (Nasdaq: EXEL) has expanded its collaboration with Invenra to include 20 additional oncology targets, enhancing their joint efforts to develop mono-specific and multi-specific antibodies for cancer treatment. Exelixis will pay Invenra an upfront fee of $15 million and additional fees for the new targets. The agreement allows Exelixis to own all antibody sequences discovered, with potential milestone payments for Invenra. This partnership aims to strengthen Exelixis' oncology pipeline and improve cancer therapy options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
Rhea-AI Summary

Exelixis reported impressive financial results for Q2 2021, with total revenues reaching $385.2 million, a 48% increase from Q2 2020. Net product revenues from CABOMETYX rose 59% year over year, driven by strong adoption of the CABOMETYX and OPDIVO combination therapy for renal cell carcinoma. The company has raised its revenue guidance for 2021, projecting total revenues between $1.3 billion and $1.4 billion. Key milestones include a supplemental NDA filing for cabozantinib in thyroid cancer and promising results from clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
-
Rhea-AI Summary

Exelixis (NASDAQ: EXEL) announced the FDA's acceptance of its supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) to treat patients aged 12 and older with radioactive iodine-refractory differentiated thyroid cancer. The FDA has granted Priority Review, with a PDUFA target action date of December 4, 2021. The sNDA is based on promising results from the COSMIC-311 pivotal trial that indicated significant progression-free survival benefits. This development could position CABOMETYX as a critical treatment option for patients lacking standard care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) will release its second quarter 2021 financial results on August 5, 2021, post-market close. A conference call is scheduled at 5:00 p.m. EDT to discuss the results and provide a business update. Access to the call will be available on their website and via phone. Exelixis focuses on oncology and has developed four commercial products, including CABOMETYX and COTELLIC, with ongoing partnerships to advance cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
-
Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) announced that Dr. Peter Lamb, its Executive VP and Chief Scientific Officer, will present at the William Blair Biotech Focus Conference on July 15, 2021, at 2:00 p.m. EDT. Interested participants can access the webcast via www.exelixis.com and should connect 15 minutes early. A replay will be available for 14 days. Founded in 1994, Exelixis focuses on oncology and has developed four commercial products, including CABOMETYX and COMETRIQ, while also collaborating with leading pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary

Exelixis and Ipsen announced the positive results of their pivotal phase 3 COSMIC-312 trial, evaluating cabozantinib with atezolizumab in advanced hepatocellular carcinoma (HCC) patients. The trial met its primary endpoint, showing a 37% reduction in disease progression or death with cabozantinib compared to sorafenib (P=0.0012). However, the secondary endpoint of overall survival did not reach statistical significance, with Exelixis anticipating low probability of achieving this at final analysis, expected in early 2022. The results will inform potential regulatory filing with the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.06%
Tags
Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) announced that Dr. Gisela M. Schwab, its President and Chief Medical Officer, is on medical leave. Dr. Schwab has been a key figure for 15 years, and her team will continue leading product development and medical affairs during her absence. The company remains focused on 2021 priorities, including upcoming results from the COSMIC-312 trial and potential regulatory filings for cabozantinib. Exelixis, recognized for its oncology innovations, emphasizes a commitment to advancing its drug pipeline while maintaining business continuity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none

FAQ

What is the current stock price of Exelixis (EXEL)?

The current stock price of Exelixis (EXEL) is $33.29 as of December 20, 2024.

What is the market cap of Exelixis (EXEL)?

The market cap of Exelixis (EXEL) is approximately 9.5B.

What is Exelixis Inc. known for?

Exelixis Inc. is known for developing and commercializing small molecule therapies aimed at improving cancer treatment.

What are the main products of Exelixis?

The main products of Exelixis are Cometriq® (cabozantinib) for thyroid cancer, Cabometyx for kidney and liver cancer, and Cotellic for melanoma.

When was Cometriq first approved?

Cometriq received its initial regulatory approval in late 2012.

Who are the key partners of Exelixis?

Exelixis has partnered with Roche to bring Cotellic to market.

What type of cancer is Cometriq used to treat?

Cometriq is used to treat metastatic medullary thyroid cancer.

What is Cabometyx used for?

Cabometyx is used for the treatment of kidney and liver cancers.

Where can I find job opportunities at Exelixis?

Job opportunities at Exelixis can be found on their official website at www.exelixis.com.

How has the financial performance of Exelixis been?

Exelixis has shown solid financial performance with steady revenue growth driven by its commercial products and pipeline.

What kind of research does Exelixis focus on?

Exelixis focuses on the research and development of innovative therapies for cancer treatment.

What is the ticker symbol for Exelixis Inc.?

The ticker symbol for Exelixis Inc. is EXEL.

Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

EXEL Stock Data

9.52B
281.04M
1.59%
89.36%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ALAMEDA